Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Fortis Healthcare Limited — Q2 FY25
Fortis Healthcare delivered a strong Q2 FY25 with consolidated revenue of INR 1,988 crore (+12.3% YoY) and EBITDA of INR 435 crore (+31.9% YoY), driving a 330 bps margin expansion to 21.9%.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Fortis Healthcare delivered a strong Q2 FY25 with consolidated revenue of INR 1,988 crore (+12.3% YoY) and EBITDA of INR 435 crore (+31.9% YoY), driving a 330 bps margin expansion to 21.9%. The hospital business led growth with revenue up 13.9% and EBITDA margins improving 300 bps to 21.4%, aided by higher occupancy (72% vs 69%) and ARPOB growth of 7.6%. Agilus Diagnostics saw margin recovery to 21.5% (24% adjusted) despite modest revenue growth of 3.4%. Management maintained guidance of 200 bps margin expansion for the hospital business for FY25, with brownfield bed additions (Manesar, Faridabad, FMRI) expected to contribute from Q4. The acquisition of 31.52% stake in Agilus for INR 1,778 crore enterprise value is on track to close by December. Key risk: slower-than-expected ramp-up of new brownfield capacity could pressure near-term margins.
फोर्टिस हेल्थकेयर ने दूसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 1,988 करोड़ रुपये रही, जो पिछले साल से 12.3% ज्यादा है। मुनाफा (EBITDA) 435 करोड़ रुपये रहा, जो 31.9% बढ़ा। कंपनी का मार्जिन (कमाई पर मुनाफे का अनुपात) 21.9% हो गया, जो पहले 18.6% था। अस्पतालों का कारोबार सबसे अच्छा रहा, जहां कमाई 13.9% बढ़ी और मार्जिन 21.4% पहुंच गया। मरीजों की संख्या बढ़ी और प्रति बिस्तर कमाई 7.6% बढ़ी। अगिलस डायग्नोस्टिक्स का मार्जिन 21.5% रहा। कंपनी ने कहा कि इस साल अस्पतालों का मार्जिन 2% और बढ़ेगा। नए बिस्तर (मानेसर, फरीदाबाद) चौथी तिमाही से फायदा देंगे। अगिलस में 31.52% हिस्सेदारी खरीद दिसंबर तक पूरी होगी। जोखिम: नए बिस्तरों से उम्मीद के मुताबिक कमाई नहीं होने पर मार्जिन पर दबाव पड़ सकता है।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Agilus top-line growth remains sluggish
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Hospital Occupancy
72%
+3pp YoY
Occupancy improved from 69% in Q2 FY24, driven by volume growth across key facilities.
Hospital ARPOB
INR 2.37 crore per annum
+7.6% YoY
ARPOB growth supported by revenue mix shift towards high-value specialties like oncology and neurosciences.
Agilus Test Volume
11.1 million
+4.7% YoY
Test volumes grew from 10.6 million in Q2 FY24, with core business growth offsetting low-value PPP business decline.
Robotic Surgery Procedures
57% growth
+57% YoY
Robotic surgeries increased sharply, reflecting adoption of advanced technology and clinical expertise.
What Changed vs Last Quarter
NEW
Brownfield bed additions of 350-400 beds in FY26
Management expects to add 350-400 beds in FY26 through brownfield expansions at Noida, FMRI, Anandapur, and BG Road.
NEW
Capex of INR 800-900 crore per year for FY25 and FY26
Annual capex includes maintenance and growth capex for both years, supporting brownfield expansions and equipment upgrades.
UPDATED
Hospital EBITDA margin expansion of 200 bps for FY25
Management reaffirmed guidance of 200 bps margin expansion for the hospital business for the full year, factoring in initial losses from Manesar.
UPDATED
Agilus EBITDA margin target of 25-26% by FY27-28
Agilus aims to achieve 25-26% EBITDA margins in 15-18 months, driven by operating leverage and cost optimization.
DROPPED
Agilus rebranding spend of INR 50 crore in FY25
Agilus plans to spend approximately INR 50 crore on rebranding expenses this fiscal year, which will be treated as one-off costs.
DROPPED
Manesar 350-bed facility to be operational in Q2 FY25
The acquired Manesar facility is expected to start operations in the ongoing quarter, initially with 100 beds, ramping up to full capacity over 18 months.
DROPPED
Agilus to return to industry growth by next year
Management expects Agilus to consolidate during FY25 and return to industry-level growth in FY26, driven by brand recovery and network expansion.
NEW RISK
Agilus top-line growth remains sluggish
Agilus revenue grew only 3.4% YoY, trailing peers, due to brand transition impact and low-value PPP business decline. Recovery to double-digit growth is uncertain.
NEW RISK
Brownfield ramp-up may pressure near-term margins
New bed additions at Manesar and other facilities are expected to initially drag EBITDA, with Manesar break-even estimated at 15 months.
NEW RISK
Legal costs remain elevated
Legal costs related to ongoing High Court cases are higher this year due to increased hearings, with no immediate resolution expected.
NEW RISK
Seasonal occupancy dip in Q3
Festival season typically reduces occupancy in Q3, which could impact sequential revenue and margin performance.
RISK GONE
Payer mix shift impacting margins
Increase in scheme business (CGHS/ECHS) and higher share of lower-margin specialties (ortho, onco) compressed hospital EBITDA margins by ~2% in Q1.
RISK GONE
Agilus underperformance and brand transition drag
Diagnostics revenue remained flat YoY, with margins declining due to rebranding costs and government provisions; recovery may take longer than expected.
RISK GONE
Legal costs from Daiichi dispute to persist
Legal costs related to the Daiichi litigation are expected to remain high this year, with potential appeals adding uncertainty.
RISK GONE
Geopolitical risks impacting medical travel
Recent developments in Bangladesh and Israel may affect international patient flows, though management expects no material impact.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24, Q3 FY24
Brownfield bed expansion plan to add ~2,200 beds, with ~710 beds expected in FY25, including the Manesar acquisition.
Mentioned in Q1 FY24, Q2 FY24
Management identified potential delays in brownfield bed commissioning as a key risk to achieving FY25 margin targets.
Mentioned in Q1 FY24, Q2 FY24
Rapid growth in medical oncology (lower margin) relative to surgical oncology could cap margin expansion despite absolute EBITDA growth.
Mentioned in Q2 FY24, Q4 FY24
Annual legal costs of ₹30-50 crore related to legacy issues (brand, forensic audit) may persist until resolution; Supreme Court stay on promoter shareholding dismissed.
Fast read
Guidance and risk preview
Management reaffirmed guidance of 200 bps margin expansion for the hospital business for the full year, factoring in initial losses from Manesar.
Agilus revenue grew only 3.4% YoY, trailing peers, due to brand transition impact and low-value PPP business decline.
View Risks →